NASDAQ:DYAI Dyadic International (DYAI) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free DYAI Stock Alerts $1.58 +0.08 (+5.33%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.48▼$1.6450-Day Range$1.29▼$1.6052-Week Range$1.19▼$2.40Volume19,030 shsAverage Volume22,453 shsMarket Capitalization$45.52 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Dyadic International alerts: Email Address Dyadic International MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside279.7% Upside$6.00 Price TargetShort InterestHealthy0.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.24) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.72 out of 5 starsMedical Sector665th out of 947 stocksBiological Products, Except Diagnostic Industry121st out of 159 stocks 3.5 Analyst's Opinion Consensus RatingDyadic International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Dyadic International has a forecasted upside of 279.7% from its current price of $1.58.Amount of Analyst CoverageDyadic International has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.85% of the float of Dyadic International has been sold short.Short Interest Ratio / Days to CoverDyadic International has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Dyadic International has recently decreased by 4.18%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDyadic International does not currently pay a dividend.Dividend GrowthDyadic International does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DYAI. Previous Next 2.0 News and Social Media Coverage News SentimentDyadic International has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Dyadic International this week, compared to 1 article on an average week.Search Interest3 people have searched for DYAI on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dyadic International insiders have not sold or bought any company stock.Percentage Held by Insiders27.30% of the stock of Dyadic International is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.58% of the stock of Dyadic International is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Dyadic International are expected to decrease in the coming year, from ($0.24) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyadic International is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyadic International is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyadic International has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Dyadic International Stock (NASDAQ:DYAI)Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design,Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.Read More DYAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DYAI Stock News HeadlinesMarch 14, 2024 | globenewswire.comDyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024March 11, 2024 | finance.yahoo.comDyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and CommercializationMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 11, 2024 | globenewswire.comCORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and CommercializationMarch 11, 2024 | globenewswire.comDyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and CommercializationMarch 1, 2024 | globenewswire.comDyadic to Attend Industry Events in MarchFebruary 29, 2024 | ca.finance.yahoo.comDYAI Aug 2024 2.500 callFebruary 29, 2024 | ca.finance.yahoo.comDYAI Apr 2024 2.500 callMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 28, 2024 | msn.comDyadic announces strategic partnership agreement to develop rabies vaccinesFebruary 28, 2024 | globenewswire.comDyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production PlatformFebruary 23, 2024 | globenewswire.comDyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease SolutionsFebruary 21, 2024 | finance.yahoo.comDyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease SolutionsFebruary 21, 2024 | finance.yahoo.comDyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease SolutionsFebruary 21, 2024 | globenewswire.comDyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease SolutionsFebruary 20, 2024 | finance.yahoo.comDYAI: Catching Up With DyadicFebruary 6, 2024 | msn.comDyadic signs R&D agreement with global biopharmaceutical companyFebruary 1, 2024 | finance.yahoo.comDyadic to Attend BIO CEO & Investor Conference and European Industry EventsJanuary 22, 2024 | finance.yahoo.comDyadic International, Inc Invites You to Join Us at The Microcap ConferenceJanuary 3, 2024 | morningstar.comDyadic International Inc DYAINovember 30, 2023 | finance.yahoo.comDyadic Attends Investor Events in DecemberNovember 29, 2023 | finance.yahoo.comDyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine CandidateNovember 22, 2023 | finance.yahoo.comShareholders in Dyadic International (NASDAQ:DYAI) are in the red if they invested three years agoNovember 20, 2023 | markets.businessinsider.comDyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in AfricaNovember 20, 2023 | finance.yahoo.comDyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in AfricaNovember 13, 2023 | markets.businessinsider.comDyadic International’s Promising Outlook: COVID-19 Vaccine Progress, Strategic Collaborations, and Financial StabilityNovember 9, 2023 | finance.yahoo.comDYAI: Third Quarter UpdateSee More Headlines Receive DYAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyadic International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/18/2024Next Earnings (Confirmed)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:DYAI CUSIPN/A CIK1213809 Webwww.dyadic.com Phone(561) 743-8333Fax561-743-8343Employees7Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+279.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,730,000.00 Net Margins-232.38% Pretax Margin-232.38% Return on Equity-71.31% Return on Assets-58.64% Debt Debt-to-Equity RatioN/A Current Ratio6.24 Quick Ratio6.24 Sales & Book Value Annual Sales$2.93 million Price / Sales15.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book4.05Miscellaneous Outstanding Shares28,810,000Free Float20,946,000Market Cap$45.52 million OptionableOptionable Beta0.58 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Mark A. Emalfarb (Age 68)Founder, CEO, President & Director Comp: $636.61kMs. Ping Wang Rawson CPA (Age 49)M.B.A., Chief Financial Officer Comp: $279.07kMr. Joseph P. HazeltonChief Business OfficerMr. Doug Pace B.A.Executive Vice President of Business DevelopmentMs. Ana Gómez RodriguezSecretary of the BoardKey CompetitorsOKYO PharmaNASDAQ:OKYOEstrella ImmunopharmaNASDAQ:ESLAEntera BioNASDAQ:ENTXIN8bioNASDAQ:INABProtara TherapeuticsNASDAQ:TARAView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 21,003 shares on 3/11/2024Ownership: 2.790%Vanguard Group Inc.Bought 21,003 shares on 2/15/2024Ownership: 2.790%Citadel Advisors LLCBought 300 shares on 2/15/2024Ownership: 0.000%Simplex Trading LLCBought 100 shares on 2/2/2024Ownership: 0.000%Chapin Davis Inc.Sold 12,000 shares on 1/11/2024Ownership: 2.868%View All Institutional Transactions DYAI Stock Analysis - Frequently Asked Questions Should I buy or sell Dyadic International stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYAI shares. View DYAI analyst ratings or view top-rated stocks. What is Dyadic International's stock price target for 2024? 1 analysts have issued 12 month price objectives for Dyadic International's shares. Their DYAI share price targets range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 279.7% from the stock's current price. View analysts price targets for DYAI or view top-rated stocks among Wall Street analysts. How have DYAI shares performed in 2024? Dyadic International's stock was trading at $1.61 at the start of the year. Since then, DYAI shares have decreased by 1.9% and is now trading at $1.58. View the best growth stocks for 2024 here. When is Dyadic International's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our DYAI earnings forecast. How can I listen to Dyadic International's earnings call? Dyadic International will be holding an earnings conference call on Thursday, March 28th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Dyadic International's earnings last quarter? Dyadic International, Inc. (NASDAQ:DYAI) released its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.03. The biotechnology company had revenue of $0.69 million for the quarter, compared to analysts' expectations of $0.61 million. Dyadic International had a negative trailing twelve-month return on equity of 71.31% and a negative net margin of 232.38%. During the same quarter in the previous year, the company posted ($0.09) earnings per share. What other stocks do shareholders of Dyadic International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dyadic International investors own include Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL), Pfizer (PFE), Advanced Micro Devices (AMD), Endeavour Silver (EDR), Mandalay Resources (MND), Alibaba Group (BABA) and Chimerix (CMRX). Who are Dyadic International's major shareholders? Dyadic International's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Chapin Davis Inc. (2.87%), Vanguard Group Inc. (2.79%), Vanguard Group Inc. (2.79%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Francisco Trust Under Agreemen, Mark A Emalfarb, Ping Wang Rawson and Ronen Tchelet. View institutional ownership trends. How do I buy shares of Dyadic International? Shares of DYAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DYAI) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.